Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination

Magalie Dosset, Charline Vauchy, Laurent Beziaud, Olivier Adotevi, Yann Godet, Magalie Dosset, Charline Vauchy, Laurent Beziaud, Olivier Adotevi, Yann Godet

Abstract

Accumulating evidence demonstrates the importance of CD4+ T cells in antitumor immune responses. Identifying promiscuous MHC class II-binding peptides derived from relevant tumor-associated antigens that specifically target CD4+ helper T cells in vivo represent a powerful approach to fully exploit these cells for anticancer immunotherapy.

Keywords: CD4 T cell; cancer vaccine; helper peptide; immunotherapy; telomerase.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3661170/bin/onci-2-e23430-g1.jpg
Figure 1. Cellular effects of universal cancer peptides-based antitumor vaccination. CTL, cytotoxic T lymphocyte; DC, dendritic cell; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFNγ, interferon γ; IL, interleukin; TCR, T-cell receptor; TH1; T helper 1; UCP, universal cancer peptides.

References

    1. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev. 2008;222:129–44. doi: 10.1111/j.1600-065X.2008.00616.x.
    1. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393:474–8. doi: 10.1038/30989.
    1. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi: 10.1038/nrc3245.
    1. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer. 2008;8:167–79. doi: 10.1038/nrc2275.
    1. Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res. 2012;18:2943–53. doi: 10.1158/1078-0432.CCR-11-3185.
    1. Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, et al. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clin Cancer Res. 2012;18:6284–95. doi: 10.1158/1078-0432.CCR-12-0896.
    1. Kobayashi H, Celis E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol. 2008;20:221–7. doi: 10.1016/j.coi.2008.04.011.
    1. Slingluff CL, Jr., Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol. 2011;29:2924–32. doi: 10.1200/JCO.2010.33.8053.
    1. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010;70:8368–77. doi: 10.1158/0008-5472.CAN-10-1322.
    1. Wong SBJ, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol. 2008;180:3122–31.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever